Analytical Data
-
Gene name
TAGAP
- Application
-
Alternative Names
IDDM21
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
B2RWW0
-
Expression Region
Met1~Phe277
-
Molecular Weight
80kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TAGAP (T-cell activation RhoGTPase-activating protein) is a crucial regulator of immune responses, particularly in T lymphocyte activation and differentiation. Research into the role of TAGAP has gained momentum due to its involvement in various immunological conditions and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. TAGAP serves as a GTPase-activating protein (GAP), primarily targeting Rho family GTPases, which modulate cytoskeletal dynamics and cellular signaling pathways critical for T-cell function. The structural and functional characterization of TAGAP as a recombinant protein has become essential for understanding its mechanism of action at the molecular level. By producing recombinant TAGAP, researchers can examine its interactions with specific GTPases and downstream effectors, paving the way for potential therapeutic interventions. Furthermore, the study of TAGAP also has implications for vaccine development and enhancing T-cell responses in cancer immunotherapy. Given its pivotal role in shaping immune responses, TAGAP represents a promising target for modulating T cell activity, and ongoing research aims to elucidate its potential as a biomarker or therapeutic target in various diseases. Recent advancements in recombinant protein technology allow for the high-yield expression and purification of TAGAP, facilitating detailed biochemical studies and functional assays to explore its impact on immune cell regulation and overall immunological health.
